1. To determine the mode of action of doxapram in man we have measured ventilation, oxygen uptake, COz production, hypoxic and hypercapnic ventilatory responses in six healthy men before and during intravenous infusion tn maintain a constant plasma level.
Introduction
Doxapram hydrochloride is a potent ventilatory stimulant which has been advocated for use in acute or chronic ventilatory failure [l] , postoperative respiratory depression [2] and respiratory depression in the newborn [3] . Early animal studies suggested that it acted by stimulating the central medullary respiratory neurons. However, the drug also increases the action potential frequency in the carotid sinus nerves. This implies that it has a direct action on the peripheral chemoreceptors [4-61. On the basis of these animal observations, a bolus injection of doxapram has been proposed as a specific test of chemoreceptor integrity in normal man [7] . To clarify the action of doxapram in man, we have measured the hypoxic and hypercapnic drives to breathing before and during doxapram infusion. We have also measured the oxygen uptake and C02 production to discover if any change in ventilatory effects of doxapram can be explained by concomitant changes in metabolic rate.
Methods

Subjects
We studied six healthy men aged 25-45 years with no previous history of cardiorespiratory disease. Their lung volumes and FEVl were within the predicted normal ranges [8] . Two subjects each smoked 20 cigaretteslday but did not smoke for 4 h before each study. All subjects gave informed consent to the study, which was approved by the local Hospital Ethical Committee. All studies were conducted while the subject was comfortably seated breathing room air from a modified Otis-McKerrow valve and mouthpiece. Expiration was through a 3.2 litres mixing chamber to a Parkinson Cowan CD4 gas meter with digital electrical output. Mixed inspired and expired gas could be sampled and analysed off-line and breath-by-breath measurements of ventilation and gas tensions were made as described below. The ECG was monitored throughout and taped music was provided through headphones to distract the subject from his environment. The side effects of doxapram and its long half-life [9] precluded a single blind cross-over study design.
Drug injiuion
Doxapram was infused by a Sage Instrument model 355D pump into a forearm vein during the second half of the study. After 20 min the infusion rate was progressively decreased to maintain a constant plasma doxapram level, which ranged from 1.6 to 3.0 pg/ml. These levels are known to be similar to those attained in patients receiving doxapram infusions at the manufacturers' recommended rate [9] . The individual infusion rates were predicted from the previous pharmacokinetic data and were known to be without serious side effects [9] . Blood was sampled at intervals from an indwelling venous cannula in the other forearm, for measurements of plasma doxapram concentration by gas-liquid chromatography [lo] . The cannulae were inserted before the control studies and their patency was maintained with heparinized sodium chloride solution (1 54 mmol/l :saline).
Plan of study
Each subject attended on two afternoons. On the first, measurements of gas exchange and ventilation were made as described in (1) below, followed by ventilatory response to progressive isocapnic hypoxia at the subject's resting end-tidal carbon dioxide tension. CO, was added to the inspired gases in amounts to increase the end-tidal Pco, by 0.5 kPa, and when ventilation and endtidal CO, were stable for at least 5 min, the progressive isocapnic hypoxia test was repeated. When ventilation and end-tidal CO, returned to their initial values, infusion of doxapram started, followed by the same sequence of measurements, blood being withdrawn for plasma doxapram concentration 20 min after starting the infusion and again before and after each of the respiratory measurements.
On the second occasion (5-10 days later) the ventilatory response to CO, was studied in duplicate (see below). Doxapram was then infused at the same rate as before, 10 min after the completion of the second rebreathing manoeuvre. CO, responses were then repeated when steadystate plasma levels of doxapram had been achieved.
There were no significant differences between the doxapram levels in the same subject between the 2 days.
Measurements
(1) Gas exchange and ventilation at rest before and during doxapram infusion. Ventilation was recorded from the dry gas meter and the pneumotachygraph in the expired line. Mixed inspired and expired gas was sampled by 50 ml syringes with a Harvard pump over three successive 3 min periods when ventilation was stable. Mixed expired gas was analysed for CO, concentration by a Uras infrared CO, meter (Godart capnograph) and for oxygen by a Servomex OAl11 paramagnetic oxygen analyser. Both instruments had previously been calibrated with gas mixtures of known oxygen, CO, and nitrogen concentrations.
(2) Ventilatov response to progressive isocapnic hypoxia. This was measured at rest by a modification of the method of Weil et al. [ l 11 . Ventilation was measured breath by breath from an integrated signal from a Fleish no. 3 pneumotachygraph in the expired line. End-tidal oxygen and CO, tensions were measured by a Varian M3 mass spectrometer previously calibrated with six oxygen, nitrogen and C 0 2 mixtures analysed by the Lloyd-Haldane apparatus. Analogue signals of the integrated pneumotachygraph signal, the mass spectrometer, CD4 gas meter and thermister in the expired gas stream were collected on-line by a DEC PDP11/40 computer. This was programmed to provide breath-by-breath measurements of respiratory frequency ( f ) , tidal volume (5, BTPS), instantaneous minute ventilation (VE inst. = f x b), end-tidal oxygen (PET02) and C 0 2 tensions (PETco,). Arterial oxygen saturation (Sao,) was measured by a Hewlett Packard 47201A ear oximeter, which is accurate to within * 2% in the range 65-100% [12] .
The composition of inspired gas was adjusted by a Rotameter mixing device, nitrogen being added over a 10 min period to produce a fall in Sao, from the resting value (98-100%) to 8045%. Any fall in PETCO;! occurring as a result of ventilatory stimulation was prevented by the addition of CO, to the inspired gas.
(3) Ventilatoly response to progressive hypercapnia in a background of relative hyperoxia. This response was measured by using the modification of the CO, rebreathing method [I31 with a 'bag in the box' technique. The subject breathed room air through a mouthpiece until the end-tidal COz tensions were stable. He then began to rebreathe from a 6 litres anaesthetic bag within a Perspex box, the bag initially containing 40% oxygen and 7% COz (balance gas nitrogen). Ventilation was measured by the pneumotachygraph recording the volume of gas displaced from the box by each breath. End-tidal COz tensions were measured at the lips by the mass spectrometer. The ventilatory response to hypercapnia was then recorded over the succeeding 4min or until the ventilation reached 50 litreslmin. After a 10 min rest period the rebreathing procedure was repeated; the results of the two studies were pooled and any points recorded when the end-tidal oxygen had fallen below 16 kPa were deleted from the subsequent analysis.
Analysis
Values are expressed as means + 1 SD. As the ear oxygen saturation varied between subjects before and after receiving doxapram, the ventilation was. standardized to an oxygen saturation of 100% (VE 100) by extrapolating from the linear regression relationship between ventilation and oxygen saturation. This extrapolated ventilation was only slightly different from the ventilation recorded at rest by both the dry gas meter and the pneumotachygraph. The subject's response to progressive hypoxia is expressed as the slope of the relationsep between ventilation and oxygen saturation (VdSaoz). The sensitivity to COz is also expressed as the slope of the relationship between end-tidal COz and ventilation (V~IPETCO~). The small numbers of subjects prepared to undertake this study precluded statistical analysis of the changes between the groups.
Results
All subjects experienced the characteristic feeling of perineal heat and body warmth associated with doxapram infusion. Two subjects developed mild tremor. Plasma doxapram concentrations varied between individuals but were relatively constant in any one subject (Fig. 1) .
Gas exchange and ventihtion at rest before and after doxapram
All the subjects had a norm$ oxygen uptake (pod, carbon 
Ventilatory response to progressive isocapnic hypoxia
The ventilatory response to hypoxia was enhanced by C 0 2 in five of the six subjects, although there was a considerable variation in the extent of this potentiation (Table 1) . Doxapram infusion increased the mean ventilatory response to hypoxia from -0.8 f 0.4 litre min-' (%SaoZ)-' to -1.63 f 0.9 litres min-' (%Sao,)-' when the measurements were carried out at the original end-tidal COz (Table 1 ). This increase in hypoxic sensitivity was very similar to that produced when the endtidal COz was increased by 0.5 kPa without doxapram, and those subjects who responded most to COz also responded markedly to doxapram. 
Ventilatory response to progressive hypercapnia
The ventilatory response to C 0 2 varied from 4.4 to 18.2 litres min-' kPa-' among the six subjects. Doxapram infusion increased the slope of this relationship significantly from 11.6 f 5.3 litres min-' kPa-' to 20.4 f 0.8 litres min-' kPa-' (Table 1) .
Discussion
Doxapram is unusual among ventilatory stimulants, since prolonged infusion both lowers the arterial Pco, and arouses unconscious patients [14, 151. Attempts to define the site of action of the drug in animals have produced conflicting results. Electro-physiological and cross-circulation studies suggested that the drug acts centrally with minimal stimulation of the carotid chemoreceptors [4, 161. However, Mitchell & Herbert [5] found that a 30-fold increase in the dose of doxapram was required to produce equivalent phrenic nerve activity in the anaesthetized cat after section of the carotid sinus nerve. This suggests that the peripheral chemoreceptors play a major role in the ventilatory stimulation produced by doxapram infusion.
Most studies of the action of doxapram in man have been carried out on anaesthetized subjects [17] or after bolus injections. In clinical practice, however, the drug is normally given by continuous intravenous infusion. Although doxapram has a long half-life with multi-exponential pharmacokinetics, we have used an infusion regimen designed t o produce a relatively constant plasma concentration over several hours [18] . Thus the plasma doxapram concentrations reached during the study are similar t o those found in patients receiving the manufacturers' recommended dosage of 2 mg/min.
Doxapram increased hypoxic sensitivity in five of our six subjects. The one subject who failed to respond had virtually no ventilatory response t o isocapnic hypoxia at his resting end-tidal C02.
This potentiation of hypoxic drive by doxapram was similar to that produced by increasing the endtidal C 0 2 tension by 0.5 kPa. When doxapram was combined with an elevated end-tidal C 0 2 tension, hypoxic sensitivity rose further in four of the six subjects. One of the two unresponsive subjects had shown little potentiation of hypoxic drive when given additional C 0 2 without doxapram. He also had the lowest ventilatory response to C 0 2 in hyperoxia. The ventilation of the other unresponsive subject was already 56 litres/min before the progressive hypoxic test. A further increase in ventilation in the final period of such a test was difficult to sustain.
Doxapram consistently increased resting ventilation and the rising resting ventilation was similar to that produced by increasing the end-tidal C02. Moreover, the ventilatory response to carbon dioxide doubled during doxapram infusion.
These studies. in conscious healthy man show that doxapram potentiated the ventilatory response to hypoxia, if such a response was present before the drug was used. The similarity between the effects of doxapram and increasing the end-tidal C 0 2 tension on the response to progressive hypoxia, may result from the drug increasing either the sensitivity of the peripheral chemoreceptors to C 0 2 or the sensitivity of the central connections.
Doxapram also increased the slope of the C 0 2 response in relative hyperoxia when input from the peripheral chemoreceptors is minimal. The changes in resting ventilation seen during doxapram infusion may reflect a non-specific hyperventilation, a result of the discomfort produced by the drug. Alternatively doxapram may enhance sensitivity to C02. Doxapram therefore appears to stimulate both peripheral and 'central' chemoreceptors in man as the initial animal studies suggested. The relative importance of these effects in lowering the arterial C02 of patients with acute ventilatory failure is unclear. Both actions may be required to enhance peripheral chemoreceptor input and relieve the C 0 2 narcosis associated with such events, but clinical studies to investigate the relative importance of these effects are not yet available.
Although doxapram is a potent ventilatory stimulant it must be given by intravenous infusion and has disagreeable side-effects. We have recently studied the effects of a new agent, almitrine, on the hypoxic and hypercapnic drives to breathing and found it to be at least as potent as doxapram in increasing hypoxic sensitivity. However, oral almitrine did not change the ventilatory response to COz or increase resting ventilation in normoxia and it was not associated with side-effects [19].
These results, which others have confirmed [20] , suggest that unlike doxapram, almitrine is a specific peripheral chemoreceptor stimulant.
Thus the effectiveness of doxapram seems to depend upon the individual's pre-existing sensitivity to hypoxia and hypercapnia and a standard dosage regimen may not be equipotent for all subjects. Moreover, the variability of response among our subjects and the evidence for a 'central' action in stimulating ventilation makes doxapram an unsuitable drug to use as a test of peripheral chemoreceptor function.
